ReviewMolecular medicine (Cambridge, Mass.)2026
Neutrophilic asthma: advances in experimental models from pathogenesis to therapeutic translation.
Review in Molecular medicine (Cambridge, Mass.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNeutrophilic asthma (NA) is a severe and therapy-resistant asthma endotype marked by persistent airway inflammation, neutrophil infiltration, and limited response to glucocorticoids. The development of targeted therapies has been hampered by insufficient mechanistic insight and the lack of physiologically relevant experimental models. MAIN BODY: This review comprehensively synthesizes current in vivo and in vitro models for NA, discussing their methodologies, mechanistic fidelity, and translational potential. Murine systems provide flexible genetic and induction platforms; rat models reliably replicate steroid resistance; and equine models spontaneously mimic chronic human disease. Advanced in vitro approaches including air-liquid interface cultures, patient-derived organoids and lung-on-a-chip devices, enable precise study of epithelial barrier dysfunction, immune crosstalk, and personalized drug responses.
conclusionBy critically evaluating these tools, our review establishes a foundation for model standardization and underscores their collective role in elucidating NA pathogenesis and advancing precision medicine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.